

# SynergyMed Collaborates with The Ohio State University to Research Novel Cancer Treatment Technology

---

COLUMBOUS, OH, UNITED STATES, July 28, 2025 /EINPresswire.com/ -- SynergyMed Devices Inc., a medical device company focused on advanced cancer treatment systems for both human and veterinary applications, has initiated a veterinary clinical study with The Ohio State University. The research centers on an innovative, noninvasive platform designed to treat superficial cancerous tumors in dogs.

“

This clinical trial has the potential to impact how we treat solid tumors in dogs and serve as a less invasive alternative or complement traditional surgery”

*Professor Laura Selmic*

The study is being conducted at Ohio State’s College of Veterinary Medicine under the direction of Laura Selmic, BVetMed (Hons), MPH, professor in the Department of Veterinary Clinical Sciences. It evaluates SynergyMed’s proprietary system, which applies microwave and radio frequency energy externally at the tumor site. Prior to energy delivery, tumors are injected with FDA-approved nanoparticles that absorb electromagnetic energy, allowing

for targeted thermal ablation of cancerous tissue—often in a single treatment session.

“The work with Ohio State marks a major milestone for SynergyMed as we expand into the veterinary field,” said Dr. Anan Copt, physicist, founder, and CEO of SynergyMed Devices Inc.

“This study also serves as a strategic early-stage effort that informs our long-term plans for human applications. We’re honored to be working with Dr. Selmic, whose clinical and academic expertise is central to this effort.”

Dr. Selmic underscored the impact translational trials like this can have on the health of both animals and humans:

“This clinical trial has the potential to impact how we treat solid tumors in dogs and serve as a less invasive alternative or complement traditional surgery.”

The outcomes of the study are expected to support further development of SynergyMed’s approach across multiple species. Insights gained will help shape the future of the company’s technology, including its use in human cancer care. This research collaboration does not constitute an endorsement of any products or services by The Ohio State University College of Veterinary Medicine.

---

### [About SynergyMed Devices Inc.](#)

SynergyMed Devices Inc. is a medical technology company [developing precision, noninvasive cancer treatment systems](#) for use in both veterinary and human medicine. The company's [platform utilizes focused electromagnetic energy and smart algorithms](#) to ablate tumors effectively while minimizing damage to surrounding tissue.

Anan Copty

SynergyMed Devices Inc

[email us here](#)

Visit us on social media:

[LinkedIn](#)

[Instagram](#)

[Facebook](#)

[YouTube](#)

[TikTok](#)

[Other](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/833605739>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.